EP1128848A4 - Verfahren zur diagnose, überwachung, bilddarstellung und behandlung von gynäkologischem krebs und prostatakrebs - Google Patents
Verfahren zur diagnose, überwachung, bilddarstellung und behandlung von gynäkologischem krebs und prostatakrebsInfo
- Publication number
- EP1128848A4 EP1128848A4 EP99954757A EP99954757A EP1128848A4 EP 1128848 A4 EP1128848 A4 EP 1128848A4 EP 99954757 A EP99954757 A EP 99954757A EP 99954757 A EP99954757 A EP 99954757A EP 1128848 A4 EP1128848 A4 EP 1128848A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- staging
- diagnosing
- monitoring
- novel method
- treating gynecological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10309398P | 1998-10-05 | 1998-10-05 | |
US103093P | 1998-10-05 | ||
PCT/US1999/023252 WO2000020043A1 (en) | 1998-10-05 | 1999-10-05 | A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1128848A1 EP1128848A1 (de) | 2001-09-05 |
EP1128848A4 true EP1128848A4 (de) | 2002-08-28 |
Family
ID=22293359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99954757A Withdrawn EP1128848A4 (de) | 1998-10-05 | 1999-10-05 | Verfahren zur diagnose, überwachung, bilddarstellung und behandlung von gynäkologischem krebs und prostatakrebs |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1128848A4 (de) |
JP (1) | JP2002526752A (de) |
CA (1) | CA2346326A1 (de) |
WO (1) | WO2000020043A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7014996B1 (en) | 1998-10-02 | 2006-03-21 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers |
GB0102562D0 (en) | 2001-02-01 | 2001-03-21 | Unilever Plc | Cosmetic products for the reduction of sweat acidity |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998007857A1 (en) * | 1996-08-19 | 1998-02-26 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
WO1999045147A1 (en) * | 1998-03-05 | 1999-09-10 | Diadexus Llc | A novel method of detecting and monitoring endometrial and uterine cancers |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001527524A (ja) * | 1996-11-12 | 2001-12-25 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ヒト乳房腫瘍特異性タンパク質 |
EP0987943B1 (de) * | 1997-06-09 | 2005-05-11 | Smithkline Beecham Corporation | Nachweis und behandlung von krebs |
-
1999
- 1999-10-05 EP EP99954757A patent/EP1128848A4/de not_active Withdrawn
- 1999-10-05 WO PCT/US1999/023252 patent/WO2000020043A1/en not_active Application Discontinuation
- 1999-10-05 CA CA002346326A patent/CA2346326A1/en not_active Abandoned
- 1999-10-05 JP JP2000573401A patent/JP2002526752A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998007857A1 (en) * | 1996-08-19 | 1998-02-26 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
WO1999045147A1 (en) * | 1998-03-05 | 1999-09-10 | Diadexus Llc | A novel method of detecting and monitoring endometrial and uterine cancers |
Non-Patent Citations (2)
Title |
---|
See also references of WO0020043A1 * |
SHIINA H. ET AL.: "Immunohistochemical analysis of estramustine binding protein with particular reference to proliferative activity on human prostatic carcinoma.", THE PROSTATE, vol. 32, no. 1, June 1997 (1997-06-01), pages 49 - 58, XP002203426 * |
Also Published As
Publication number | Publication date |
---|---|
JP2002526752A (ja) | 2002-08-20 |
CA2346326A1 (en) | 2000-04-13 |
WO2000020043A1 (en) | 2000-04-13 |
EP1128848A1 (de) | 2001-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1105528A4 (de) | Verfahren zur diagnose, überwachung, klassifizierung, bildgebungund behandlung von brustkrebs | |
EP1082459A4 (de) | Neue methode zur diagnose, überwachung und bestimmung des stadiums von lungenkrebs | |
EP1239874A4 (de) | Methode zur diagnose, überwachung, einstufung, bilddarstellung und behandlung von prostatakrebs | |
HK1044816A1 (zh) | 診斷和檢測惡性乳腺癌的方法 | |
GB2340152B (en) | Multiple string completion apparatus and method | |
AU6688598A (en) | Method for diagnosing and staging prostate cancer | |
GB2344123B (en) | Well logging method and apparatus | |
EP1131095A4 (de) | Methode zur diagnose, überwachung, feststellung der krankheitsstufe, darstellung und behandlung von prostatakrebs | |
HUP9902009A3 (en) | Lamp and method of its operation | |
GB2344883B (en) | Flame monitoring methods and apparatus | |
EP1267934A4 (de) | Neues verfahren zur diagnose, überwachung, statusbestimmung, bildmässiger darstellung und behandlung von brustkrebs | |
EP1104486A4 (de) | Neues verfahren zur diagnose, zur verlaufsbeobachtung und zum abbilden von lungenkrebs | |
AU4076399A (en) | Gas well dewatering method and device | |
EP1107798A4 (de) | Neues verfahren zur diagnose, überwachung, klassifizierung, bildgebung und behandlung von kolonkrebs | |
EP1082460A4 (de) | Neuartiges verfahren zur diagnose, zur überwachung und verlaufsbeobachtung von prostatakrebs | |
EP0918989A4 (de) | Methode zur bestimmung gynäkologischer karzinome | |
EP1128848A4 (de) | Verfahren zur diagnose, überwachung, bilddarstellung und behandlung von gynäkologischem krebs und prostatakrebs | |
EP1126877A4 (de) | Methode zur diagnose, überwachung, feststellung der krankheitsstufe, darstellung und behandlung von prostatakrebs | |
EP1117833A4 (de) | Ein neuartiges verfahren zur diagnose, feststellung, einstufung, darstellung sowie behandlung gastrointestinaler krebserkrankungen | |
GB9825583D0 (en) | Pipe lining method | |
PL341667A1 (en) | Method of treating cooped | |
EP1169066A4 (de) | Verfahren zur diagnostik, überwachung, stadiumfeststellung, bildgebung und behandlung von gynaekologischer krebs | |
EP1227841A4 (de) | Ein neuartiges verfahren zur diagnose, darstellung, bewertung, bildgebung und behandlung von krebs | |
ZA976814B (en) | A novel method of detecting and treating cancer. | |
EP1250149A4 (de) | Neues verfahren zur diagnose, überwachung, einstufung, bilddarstellung und behandlung von krebs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010508 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DIADEXUS, INC. |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 39/395 A, 7C 12Q 1/00 B, 7C 12Q 1/68 B, 7G 01N 33/53 B, 7G 01N 33/567 B, 7G 01N 33/574 B, 7A 61K 51/10 B, 7A 61P 35/00 B, 7A 61K 47/48 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020712 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20031013 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20051129 |